KalVista Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) is a biopharmaceutical company focused on the discovery, development, and commercialization of oral small-molecule protease inhibitors targeting diseases driven by the kallikrein-kinin system, principally hereditary angioedema (HAE); its lead product, EKTERLY (sebetralstat), is an FDA-approved oral plasma kallikrein inhibitor for on-demand treatment of acute HAE attacks in patients aged 12 years and older, with recent European approval and commercial launch underway; the company advances an oral Factor XIIa inhibitor pipeline for HAE prophylaxis and potential applications in inflammation and thrombosis. Founded in 2011 and headquartered in Framingham, Massachusetts following a 2024 lease for new corporate and laboratory facilities, KalVista operates primarily in the United States, Europe, and Japan, serving patients with rare diseases through targeted therapies that offer convenience over injectables. Recent developments include a September 2025 upsized US$125 million convertible bond financing to support EKTERLY commercialization through 2027; an April 2025 exclusive licensing agreement with Kaken Pharmaceutical for sebetralstat commercialization in Japan, yielding a $11 million upfront payment and potential mid-twenties royalties; enhanced royalty terms with DRI Healthcare following a $22 million optional payment in 2024; and fiscal year 2025 financial results reflecting operational advancements in HAE treatment.
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista Pharmaceuticals Presents New Data Highlighting the Burden of Injectable On-Demand Treatment in Young Children with Hereditary Angioedema
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV
Stock Market Today, April 29: KalVista Pharmaceuticals Surges on Chiesi Group Acquisition Announcement
Shareholder Alert: Ademi LLP investigates whether KalVista Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of KalVista Pharmaceuticals, Inc. (NASDAQ: KALV)
KALV Stock Alert: Halper Sadeh LLC is Investigating Whether KalVista Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Italian drugmaker Chiesi to buy KalVista for $1.9 billion
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio
Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Paul Audhya Sells 2,686 Shares of Stock
KalVista Pharmaceuticals (NASDAQ:KALV) Insider Nicole Sweeny Sells 1,862 Shares
KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,862 Shares of Stock
KalVista Pharmaceuticals Touts EKTERLY Launch: Nearly $50M in Under 6 Months, 20% Patient Reach
KalVista Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference
KalVista Pharmaceuticals: Ekterly's Launch Momentum Keeps The Bull Case Alive